The effects of NIH, FDA cuts will be felt for decades, CBO report estimates

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A report from the nonpartisan Congressional Budget Office said that proposed cuts at NIH could lead to a decrease in the number of new drugs that come to market in the next three decades. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).

Multiple components of the healthcare and public health systems are currently under scrutiny. One of them is reportedly the U.S. Preventive Services Task Force (USPSTF: “Task Force”), established in 1984 and managed by the Agency for Healthcare Research and Quality.  It was created to maintain an ongoing evaluation of disease prevention and screening interventions that...

Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login